Company Overview
| Stock Name | 中國泰凌醫藥集團有限公司 |
|---|---|
| Stock Code | 01011 |
| Company Full Name | 中國泰凌醫藥集團有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事投資研發、生產及銷售藥品，以及提供醫藥市場推廣及宣傳服務。 |
| Listing Date | 2011-04-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港干諾道中168-200號信德中心西座21樓2102室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.ntpharma.com |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 4.54 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 162,093,890 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 3.82 |
|---|---|
| First Day Open | HK$ 4.2 |
| First Day Change | -15.86% |
| First Day Volume | 130166000.0 |
| First Day Turnover | 525403000.0 |
Use of Proceeds
| Use of Proceeds | 1、約25%或267.6百萬港元，將主要用于透過自然發 展及合并與收購的方式擴展及提升我們的分銷網絡（以疫苗業務為主）。 ； 2、約25%或267.6百萬港元，將用于提升及擴展我們的基礎設施； 3、約10%或107.1百萬港元，將用作擴充我們的疫苗及藥品推廣團隊； 4、約20%或214.0百萬港元，將用作透過取得其他疫苗及藥品分銷及／或推廣權特許權擴展我們產品的投資組合； 5、約20%或214.0百萬港元，將用于向知名的海外供應商采購進口疫苗或藥品。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (2)
UBS Securities Hong Kong Limited CE BIN466
高盛（亚洲）有限责任公司 CE ACC536
Joint Lead Managers (2)
UBS Securities Hong Kong Limited CE BIN466
高盛（亚洲）有限责任公司 CE ACC536
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 吳鐵 |
|---|---|
| Company Secretary | 李怡芳 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 楊宗孟(27.78%);吳鐵及家族成員(21.18%) |
|---|
